- TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
- Aileron Therapeutics Announces Pricing of Initial Public Offering
- Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors
- Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
- ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board
- Catalyst Pharmaceuticals Joins Russell 3000 Index
- Novel Findings Obtained with the PURE EP System to be Presented at American Heart Association’s BCVS Scientific Sessions 2017
- Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
- Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain
- Walter Reed National Military Medical Center Acquires a Brainsway Deep TMS System to Enhance its Treatment of Depression
